Friday, September 25, 2020 Daily Archives

Catalent adds early-stage plant to its blooming(ton) fill/finish business

by

CDMO Catalent says it is looking to serve fill and finish demand for early-phase customers in its $14 million acquisition of a second facility in Bloomington, Indiana. Three years after AB BioTechnologies broke ground on a 23,000 square-foot facility, fellow contract development and manufacturing organization (CDMO) Catalent has acquired it for $14 million – $3.5 million more than the 2017 investment. The facility adds clinical and small-scale commercial manufacturing for injectable drugs to Catalent’s growing fill and finish network and…

September 25, 2020

Combined Therapeutics wins $250,000 MilliporeSigma Advance Biotech Grant

by

MilliporeSigma has awarded MIT spin-out Combined Therapeutics a cheque for $250,000 as the winner of its 2020 Advance Biotech Grant. Combined Therapeutics (CTx) is an early stage startup developing next generation virotherapies targeted with nucleic acids. The pre-clinical biotech aims to develop therapies to treat liver cancer using its targeted oncolytic platform. The firm – founded by MIT professors Robert Langer and Dan Anderson, along with entrepreneur Romain Micol – was the prestigious winner Thursday of the MilliporeSigma Advance Biotech…

September 25, 2020

Accelerating mRNA-Based Therapy Development with Scalable Purification of In Vitro Transcribed mRNA

by

This webcast features: Kelly Flook, Senior Product Manager, Purification Products, Thermo Fisher Scientific The diversity of potential mRNA-based therapies has led to increased interest in using synthetic mRNA as a tool in the treatment of multiple diseases, such as cancer, stem cell therapies, and infectious diseases. Nevertheless, obtaining larger quantities of synthetic mRNA for clinical treatment remains a challenge. Currently available mRNA purification methods are becoming a bottleneck for large-scale manufacture as the limits of research-scale purification techniques are realized.…

September 25, 2020

Humanigen strikes third manufacturing deal for COVID-19 therapy

by

Humanigen has partnered with Thermo Fisher for the manufacture of its potential COVID-19 therapy lenzilumab as it enters Phase III trials. Lenzilumab is being explored as a treatment for ‘cytokine storm’, an overreaction of the immune system, which has occurred in those suffering from the disease. Humanigen agreed the deal with Thermo Fisher in anticipation of a potential approval for Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) later this year. The two partners have agreed…

September 25, 2020